THINPAD

Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance

 Coordinatore UNIVERSITA' DEGLI STUDI DI SIENA 

 Organization address address: VIA BANCHI DI SOTTO 55
city: SIENA
postcode: 53100

contact info
Titolo: Prof.
Nome: Maurizio
Cognome: Botta
Email: send email
Telefono: +39 0577234306

 Nazionalità Coordinatore Italy [IT]
 Totale costo 7˙505˙987 €
 EC contributo 5˙691˙950 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-2
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2016-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITA' DEGLI STUDI DI SIENA

 Organization address address: VIA BANCHI DI SOTTO 55
city: SIENA
postcode: 53100

contact info
Titolo: Prof.
Nome: Maurizio
Cognome: Botta
Email: send email
Telefono: +39 0577234306

IT (SIENA) coordinator 1˙103˙750.00
2    IRBM SCIENCE PARK SPA

 Organization address address: VIA PONTINA KM 30600
city: POMEZIA RM
postcode: 40

contact info
Titolo: Dr.
Nome: Micol
Cognome: Estrella
Email: send email
Telefono: +39 0691093269
Fax: +39 0691093654

IT (POMEZIA RM) participant 2˙386˙700.00
3    UNIVERSITE DE STRASBOURG

 Organization address address: rue Blaise Pascal 4
city: Strasbourg
postcode: 67070

contact info
Titolo: Mrs.
Nome: Sandrine
Cognome: Schott
Email: send email
Telefono: 33368851124

FR (Strasbourg) participant 964˙500.00
4    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

 Organization address address: CALLE ROSSELLO 149 PUERTA BJS
city: BARCELONA
postcode: 8036

contact info
Titolo: Ms.
Nome: Pastora
Cognome: Martinez Samper
Email: send email
Telefono: 34932275707
Fax: 34932279205

ES (BARCELONA) participant 762˙750.00
5    VIROSTATICS SRL

 Organization address address: VIALE UMBERTO I 46
city: SASSARI
postcode: 7100

contact info
Titolo: Dr.
Nome: Franco
Cognome: Lori
Email: send email
Telefono: +39 998639

IT (SASSARI) participant 474˙250.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

small    clinical    drug    nc    molecules    drugs    resistant    sme    resistance    strains    conserved    sequence    anti    hiv    replication    monitor   

 Obiettivo del progetto (Objective)

'AIDS is one of the most serious pandemic diseases of the modern era. Although current therapies based on targeting key processes of the HIV replication cycle are potent and selective, several clinical failures are recorded due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies. The objective of the THINPAD proposal is to discover and develop novel anti-HIV agents targeting the HIV nucleocapsid protein(NC), which is one of the most conserved sequence within HIV strains and is highly required for HIV replication, being therefore a primary target to overcome antiretroviral drug-resistance. The proposal originates from the successful FP6 TRIoH project and presents a multidisciplinary approach to develop anti-HIV drugs, ready for early clinical trials, that could be resistant to viral mutation since targeting a highly conserved sequence. The consortium consists of experts in the anti-HIV field which have an extensive expertise in targeting NC. Partner 1 has studied the NC dynamics and discovered small molecule NC modulators by in silico approaches. Partner 2 has developed biophysical methods to monitor the NC functions and the interaction with small molecules. Partner 3 developed a complete approach of biochemistry-, retrovirology- and microscopy-based techniques to monitor NC during HIV assembly, maturation and reverse transcription. Partner 4 is a SME founded by scientists who participated in the development of Raltegravir, which will have a leading role in the project together with Partner 5 (SME) by driving the discovery phase and pre-clinical investigation, favouring the translation of results into innovative applications for health. It is worth noting that the consortium already possesses small molecules endowed with low-micromolar inhibitory activity in cell against HIV and active against resistant strains. Notably, these molecules interact with the NC but not with the usual anti-HIV targets'

Altri progetti dello stesso programma (FP7-HEALTH)

FIGHT-MG (2009)

"Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy."

Read More  

PHASE (2009)

A PHArmacogenomic study of Statins in the Elderly at risk for cardiovascular disease

Read More  

BIOSTAT-CHF (2010)

A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure

Read More